1. McBride WG. Thalidomide and congenital abnormalities. Lancet 1961;2:1358.
2. Waxman HA. The lessons of Vioxx-drug safety and sales. N Engl J Med 2005;352:2576-2578.
3. World Health Organization. The importance of pharmacovigilance 2002.
4. Wood SF, Perosino KL. Increasing transparency at the FDA: the impact of the FDA Amendments Act of 2007. Public Health Rep 2008;123:527-530.
5. Permanand G, Mossialos E, McKee M. Regulating medicines in Europe: the European Medicines Agency, marketing authorisation, transparency and pharmacovigilance. Clin Med 2006;6:87-90.
6. U.S. Food and Drug Administration. The Food and Drug Administration Amendments Act of 2007 (FDAAA) 2007.
7. European Commission. Volume 9A of the Rule Governing Medicinal Products in the European Union ; Guidelines on Pharmacovigilance for Medicinal Products for Human Use 2008.
8. American Society of Hospital Pharmacists. ASHP guidelines on preventing medication errors in hospitals. Am J Hosp Pharm 1993;50:305-314.